Cargando…

Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial

BACKGROUND: Butorphanol slightly influences the respiratory and circulatory systems, has a better effect on relieving the discomfort caused by mechanical traction, and has a low incidence of postoperative nausea and vomiting (PONV). Combined butorphanol and propofol may suppress postoperative viscer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Wang, Xinyan, Liu, Haiyang, Han, Ruquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044711/
https://www.ncbi.nlm.nih.gov/pubmed/36977981
http://dx.doi.org/10.1186/s12871-023-02053-9
_version_ 1784913413989728256
author Wang, Jing
Wang, Xinyan
Liu, Haiyang
Han, Ruquan
author_facet Wang, Jing
Wang, Xinyan
Liu, Haiyang
Han, Ruquan
author_sort Wang, Jing
collection PubMed
description BACKGROUND: Butorphanol slightly influences the respiratory and circulatory systems, has a better effect on relieving the discomfort caused by mechanical traction, and has a low incidence of postoperative nausea and vomiting (PONV). Combined butorphanol and propofol may suppress postoperative visceral pain, which is avoidable in gastrointestinal endoscopy. Thus, we hypothesized that butorphanol could decrease the incidence of postoperative visceral pain in patients undergoing gastroscopy and colonoscopy. METHODS: This was a randomized, placebo-controlled, and double-blinded trial. Patients undergoing gastrointestinal endoscopy were randomized to intravenously receive either butorphanol (Group I) or normal saline (Group II). The primary outcome was visceral pain after the procedure 10 min after recovery. The secondary outcomes included the rate of safety outcomes and adverse events. Postoperative visceral pain was defined as a visual analog scale (VAS) score ≥ 1. RESULTS: A total of 206 patients were enrolled in the trial. Ultimately, 203 patients were randomly assigned to Group I (n = 102) or Group II (n = 101). In total, 194 patients were included in the analysis: 95 in Group I and 99 in Group II. The incidence of visceral pain at 10 min after recovery was found to be statistically lower with butorphanol than with the placebo (31.5% vs. 68.5%, respectively; RR: 2.738, 95% CI [1.409–5.319], P = 0.002), and the notable difference was in pain level or distribution of visceral pain (P = 0.006). CONCLUSIONS: The trial indicated that adding butorphanol to propofol results in a lower incidence of visceral pain after surgery without noticeable fluctuations in circulatory and respiratory functions for gastrointestinal endoscopy patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT04477733 (PI: Ruquan Han; date of registration: 20/07/2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12871-023-02053-9.
format Online
Article
Text
id pubmed-10044711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100447112023-03-29 Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial Wang, Jing Wang, Xinyan Liu, Haiyang Han, Ruquan BMC Anesthesiol Research BACKGROUND: Butorphanol slightly influences the respiratory and circulatory systems, has a better effect on relieving the discomfort caused by mechanical traction, and has a low incidence of postoperative nausea and vomiting (PONV). Combined butorphanol and propofol may suppress postoperative visceral pain, which is avoidable in gastrointestinal endoscopy. Thus, we hypothesized that butorphanol could decrease the incidence of postoperative visceral pain in patients undergoing gastroscopy and colonoscopy. METHODS: This was a randomized, placebo-controlled, and double-blinded trial. Patients undergoing gastrointestinal endoscopy were randomized to intravenously receive either butorphanol (Group I) or normal saline (Group II). The primary outcome was visceral pain after the procedure 10 min after recovery. The secondary outcomes included the rate of safety outcomes and adverse events. Postoperative visceral pain was defined as a visual analog scale (VAS) score ≥ 1. RESULTS: A total of 206 patients were enrolled in the trial. Ultimately, 203 patients were randomly assigned to Group I (n = 102) or Group II (n = 101). In total, 194 patients were included in the analysis: 95 in Group I and 99 in Group II. The incidence of visceral pain at 10 min after recovery was found to be statistically lower with butorphanol than with the placebo (31.5% vs. 68.5%, respectively; RR: 2.738, 95% CI [1.409–5.319], P = 0.002), and the notable difference was in pain level or distribution of visceral pain (P = 0.006). CONCLUSIONS: The trial indicated that adding butorphanol to propofol results in a lower incidence of visceral pain after surgery without noticeable fluctuations in circulatory and respiratory functions for gastrointestinal endoscopy patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT04477733 (PI: Ruquan Han; date of registration: 20/07/2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12871-023-02053-9. BioMed Central 2023-03-28 /pmc/articles/PMC10044711/ /pubmed/36977981 http://dx.doi.org/10.1186/s12871-023-02053-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Jing
Wang, Xinyan
Liu, Haiyang
Han, Ruquan
Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title_full Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title_fullStr Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title_full_unstemmed Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title_short Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
title_sort effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044711/
https://www.ncbi.nlm.nih.gov/pubmed/36977981
http://dx.doi.org/10.1186/s12871-023-02053-9
work_keys_str_mv AT wangjing effectofbutorphanolonvisceralpaininpatientsundergoinggastrointestinalendoscopyarandomizedcontrolledtrial
AT wangxinyan effectofbutorphanolonvisceralpaininpatientsundergoinggastrointestinalendoscopyarandomizedcontrolledtrial
AT liuhaiyang effectofbutorphanolonvisceralpaininpatientsundergoinggastrointestinalendoscopyarandomizedcontrolledtrial
AT hanruquan effectofbutorphanolonvisceralpaininpatientsundergoinggastrointestinalendoscopyarandomizedcontrolledtrial